Summary & Overview
CPT 90589: Chikungunya Vaccine, Intramuscular, Live Attenuated
CPT code 90589 denotes a live, attenuated chikungunya virus vaccine administered via intramuscular injection. This code identifies the vaccine product itself and is relevant nationally as chikungunya prevention becomes a higher priority for public health programs and outpatient immunization services. Use of this code enables consistent reporting for coverage decisions, inventory tracking, and aggregate vaccine uptake assessments.
Key payers typically relevant for coverage and claims processing include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks and policy-oriented context around payer coverage patterns, coding and billing considerations for vaccine administration services, and clinical context for where and how this vaccine is typically delivered. The analysis outlines common modifiers and service line implications where available, and notes areas where input data was not provided.
This summary is intended for administrators, coding professionals, and payers seeking a concise reference to the clinical and billing identity of CPT code 90589, its role in outpatient vaccination workflows, and the payer landscape commonly involved in vaccine reimbursement discussions.
Billing Code Overview
CPT code 90589 represents a vaccine product administered intramuscularly to protect against chikungunya virus. The vaccine uses a live, attenuated (weakened) virus to stimulate an immune response.
Service Type: Vaccine administration — intramuscular
Typical Site of Service: Outpatient clinic, primary care office, public health clinic, or designated vaccination site.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 32-year-old adult presents to a public health clinic for routine immunization prior to travel to a chikungunya-endemic region. The patient has no acute illness, has completed screening for contraindications to live vaccines (no pregnancy, no severe immunocompromise, no recent receipt of blood products), and consents to vaccination. The clinic nurse verifies immunization history, documents prior adverse reactions, and performs intramuscular administration of the live, attenuated chikungunya vaccine using standard aseptic technique. Post-vaccination, the patient is observed for 15–30 minutes for immediate adverse reactions. Documentation includes vaccine lot number, expiration date, administration site, dose, informed consent, and any observed adverse events. Billing uses 90589 for the vaccine product administered intramuscularly to protect against chikungunya virus. Typical sites of service include outpatient clinics, public health vaccination centers, travel medicine clinics, and community health centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no special circumstances apply to the service. |
22 |